Guideline-Based Antibiotics and Mortality in Healthcare-Associated Pneumonia
- 510 Downloads
Guidelines recommend administration of antibiotics with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa for treatment of healthcare-associated pneumonia (HCAP). It is unclear if this therapy improves outcomes for patients with HCAP.
To determine if administration of guideline-similar therapy (GST) was associated with a reduction in 30-day mortality for HCAP.
Multi-center retrospective study.
Thirteen hundred and eleven admissions for HCAP in six Veterans Affairs Medical Centers.
Each admission was classified as receiving GST, anti-MRSA or anti-pseudomonal components of GST, or other non-HCAP therapy initiated within 48 hours of hospitalization. Association between 30-day mortality and GST was estimated with a logistic regression model that included GST, propensity to receive GST, probability of recovering an organism from culture resistant to antibiotics traditionally used to treat community-acquired pneumonia (CAP-resistance), and a GST by CAP-resistance probability interaction.
Odds ratios and 95% confidence intervals [OR (95% CI)] of 30-day mortality for patients treated with GST and predicted probability of recovering a CAP-resistant organism, and ratio of odds ratios [ROR (95% CI)] for treatment by CAP-resistance probability interaction.
Receipt of GST was associated with increased odds of 30-day mortality [OR = 2.11 (1.11, 4.04), P = 0.02)] as was the predicted probability of recovering a CAP-resistant organism [OR = 1.67 (1.26, 2.20), P < 0.001 for a 25% increase in probability]. An interaction between predicted probability of recovering a CAP-resistant organism and receipt of GST demonstrated lower mortality with GST at high probability of CAP resistance [ROR = 0.71(≤1.00) for a 25% increase in probability, P = 0.05].
For HCAP patients with high probability of CAP-resistant organisms, GST was associated with lower mortality. Consideration of the magnitude of patient-specific risk for CAP-resistant organisms should be considered when selecting HCAP therapy.
KEY WORDSpneumonia anti-bacterial agents guideline methicillin-resistant Staphylococcus aureus Pseudomonas aeruginosa healthcare-associated infection
- 10.Madaras-Kelly KJ, Remington RE, Fan VS, Sloan KL. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J Hosp Med. 2011. doi:10.1002/jhm.942 [Epub ahead of print].
- 13.Højsgaard S, Halekoh U, Yan J. The R package geepack for generalized estimating equations. Journal of Statistical Software. 2006;15(2):1–11.Google Scholar
- 14.Madaras-Kelly KJ, Remington RE, Fan VS, Sloan KL. The Impact of Guideline Recommended Therapy on the Outcome of Health Care Associated Pneumonia (HCAP). 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Il.; 2011. Abstract 1453.Google Scholar
- 18.Falcone M, Corrao S, Venditti M, Serra P,Licata G. Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. Intern Emerg Med. 2011;6(5):431–6.Google Scholar
- 19.Mangino JE, Peyrani P, Ford KD, et al. Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Crit Care. 2011;15:R38.PubMedCrossRefGoogle Scholar
- 25.Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, Durocher A. Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. Clin Microbiol Infect. 2010;16:902–8.PubMedGoogle Scholar